Skip to main content

Table 1 Characteristics of the 9 randomized controlled trials included in the analysis

From: Effects of resveratrol on glucose control and insulin sensitivity in subjects with type 2 diabetes: systematic review and meta-analysis

Study Study design Population Duration Resveratrol group Control group Outcomes
Brasnyo et al. Randomized placebo-controlled double-blinded parallel clinical trial N = 19 patients with T2DM 4 weeks N = 10;10 mg/d N = 9; Placebo Fasting plasma glucose, fasting insulin, HbA1c, HOMA-IR
Bhatt et al. Open-label, randomized, controlled trial N = 57 patients
with T2DM
3 months N = 28;250 mg/d N = 29; Empty-control Fasting plasma glucose, HbA1c
Movahed et al. Randomized placebo-controlled double-blinded parallel clinical trial N = 64 patients
with T2DM
45 days N = 33;1 g/d N = 31; Placebo Fasting plasma glucose, fasting insulin, HbA1c, HOMA-IR
Goh et al. Randomized double-blind N = 10 patients
with T2DM
12 weeks N = 5;3 g/d N = 5; Placebo Fasting plasma glucose, fasting insulin, HbA1c, HOMA-IR
Tome-Carneiro et al. Randomized placebo-controlled triple -blinded parallel clinical trial N = 35 patients with T2DM 12 months N = 13;
RSV-enriched grape extract (8 mg/d)
N = 22; Placebo Fasting plasma glucose, HbA1c
Bashmakov et al. Randomized placebo-controlled examiner -blinded parallel clinical trial N = 24 patients with diabetic foot syndrome 60 days N = 14; 50 mg/day N = 10; Placebo Fasting plasma glucose, fasting insulin
Thazhath et al. Randomized, double-blind, crossover design N = 14 patients with T2DM 5 weeks N = 14;1 g/d N = 14; Placebo Fasting plasma glucose, HbA1c
Timmers et al. Randomized double-blind crossover study N = 17 patients with T2DM 30 days N = 17;150 mg/d N = 17; Placebo Fasting plasma glucose, fasting insulin, HbA1c, HOMA-IR
Javid et al. Randomized placebo-controlled double-blinded parallel clinical trial N = 43 patients with T2DM 4 weeks N = 21;480 mg/d N = 22; Placebo Fasting plasma glucose, fasting insulin, HOMA-IR
  1. T2DM type 2 diabetes mellitus, HOMA-IR homeostasis model assessment of insulin resistance, HbA1C glycated hemoglobin A